研究論文 Publications

  1. Plakas K, Hsieh CJ, Guarino DS, Hou C, Chia WK, Young A, Schmitz A, Ho YP, Weng CC, Lee H, Li S, Graham TJA, Mach RH. A Small-molecule Antagonist Radiotracer for Positron Emission Tomography Imaging of the Mu Opioid Receptor. bioRxiv [Preprint]. 2024 Oct 12:2024.10.12.618019. doi: 10.1101/2024.10.12.618019. PMID: 39415998; PMCID: PMC11482899.

  2. Chung YH, Ho YP, Farn SS, Tsai WC, Li ZX, Lin TY, Weng CC. In vivo SPECT imaging of Tc-99 m radiolabeled exosomes from human umbilical-cord derived mesenchymal stem cells in small animals. Biomed J. 2024 Apr 16:100721. doi: 10.1016/j.bj.2024.100721. Epub ahead of print. PMID: 38636899.

  3. Janssen B, Tian G, Lengyel-Zhand Z, Hsieh CJ, Lougee MG, Riad A, Xu K, Hou C, Weng CC, Lopresti BJ, Kim HJ, Pagar VV, Ferrie JJ, Garcia BA, Mathis CA, Luk K, Petersson EJ, Mach RH. Identification of a Putative α-synuclein Radioligand Using an in silico Similarity Search. Mol Imaging Biol. 2023 Mar 29. doi: 10.1007/s11307-023-01814-9. Epub ahead of print. PMID: 36991273.

  4. Chung YH, Hung TH, Yu CF, Tsai CK, Weng CC, Jhang F, Chen FH, Lin G. Glycolytic Plasticity of Metastatic Lung Cancer Captured by Noninvasive 18F-FDG PET/CT and Serum 1H-NMR Analysis: An Orthotopic Murine Model Study. Metabolites. 2023 Jan 9;13(1):110. doi: 10.3390/metabo13010110. PMID: 36677035; PMCID: PMC9866275.

  5. Weng CC, Riad A, Lieberman BP, Xu K, Peng X, Mikitsh JL, Mach RH. Characterization of Sigma-2 Receptor-Specific Binding Sites Using [3H]DTG and [125I]RHM-4. Pharmaceuticals (Basel). 2022 Dec 15;15(12):1564. doi: 10.3390/ph15121564. PMID: 36559015; PMCID: PMC9784403.

  6. Chou PY, Lee D,Weng CC, Wu RC, Liao CT, Liu SJ. Bone Morphogenetic Protein-,Antimicrobial Agent-, and Analgesic-Incorporated Nanofibrous Scaffolds for theTherapy of Alveolar Clefts. Pharmaceutics. 2022 Feb 8;14(2):374. doi:10.3390/pharmaceutics14020374. PMID: 35214106; PMCID: PMC8878068.

  7. Ferrie JJ, Lengyel-Zhand Z, Janssen B, Lougee MG, Giannakoulias S, Hsieh CJ,Pagar VV, Weng CC, Xu H, Graham TJA, Lee VM, Mach RH, Petersson EJ.Identification of a nanomolar affinity α-synuclein fibril imaging probe byultra-high throughput <i>in silico</i> screening. Chem Sci. 2020 Sep10;11(47):12746-12754. doi: 10.1039/d0sc02159h. PMID: 33889379; PMCID:PMC8047729.
  8. Riad A, Lengyel-Zhand Z, Zeng C, Weng CC, Lee VM, Trojanowski JQ, Mach RH.The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsiblefor the Cellular Uptake of Aβ42 and Its Protein Aggregates. Mol Neurobiol. 2020Sep;57(9):3803-3813. doi: 10.1007/s12035-020-01988-1. Epub 2020 Jun 23. PMID:32572762; PMCID: PMC7415709.
  9. Weng CC, Hsiao IT, Yang QF, Yao CH, Tai CY, Wu MF, Yen TC, Jang MK, Lin KJ.Characterization of <sup>18</sup>F-PM-PBB3 (<sup>18</sup>F-APN-1607) Uptake inthe rTg4510 Mouse Model of Tauopathy. Molecules. 2020 Apr 10;25(7):1750. doi:10.3390/molecules25071750. PMID: 32290239; PMCID: PMC7181044.
  10. Sellmyer MA, Richman SA, Lohith K, Hou C, Weng CC, Mach RH, O'Connor RS,Milone MC, Farwell MD. Imaging CAR T Cell Trafficking with eDHFR as a PETReporter Gene. Mol Ther. 2020 Jan 8;28(1):42-51. doi:10.1016/j.ymthe.2019.10.007. Epub 2019 Oct 15. PMID: 31668558; PMCID:PMC6953896.
  11. Weng CC, Carlin S, Hou C, Metz T, Li S, Lee H, Xu K, Makvandi M, Mach RH.Correlation analysis of [<sup>18</sup>F]ROStrace using ex vivo autoradiographyand dihydroethidium fluorescent imaging in lipopolysaccharide-treated animals.Biochem Biophys Res Commun. 2019 Aug 20;516(2):397-401. doi:10.1016/j.bbrc.2019.06.062. Epub 2019 Jun 17. PMID: 31221481.
  12. Makvandi M, Lee H, Puentes LN, Reilly SW, Rathi KS, Weng CC, Chan HS, Hou C,Raman P, Martinez D, Xu K, Carlin SD, Greenberg RA, Pawel BR, Mach RH, Maris JM,Pryma DA. Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to HumanNeuroblastoma in Preclinical Models. Mol Cancer Ther. 2019 Jul;18(7):1195-1204.doi: 10.1158/1535-7163.MCT-18-0837. Epub 2019 May 9. PMID: 31072830; PMCID:PMC6606392.
  13. Reilly SW, Riad AA, Hsieh CJ, Sahlholm K, Jacome DA, Griffin S, Taylor M,Weng CC, Xu K, Kirschner N, Luedtke RR, Parry C, Malhotra S, Karanicolas J, MachRH. Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce DopamineD<sub>3</sub> Receptor (D<sub>3</sub>R) Ligand Promiscuity across HighlyConserved Aminergic G-Protein-Coupled Receptors (GPCRs). J Med Chem. 2019 May23;62(10):5132-5147. doi: 10.1021/acs.jmedchem.9b00412. Epub 2019 May 6. PMID:31021617.
  14. Elmi A, Makvandi M, Weng CC, Hou C, Clark AS, Mach RH, Mankoff DA. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined withEndocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and[<sup>18</sup>F]ISO-1 PET/CT. Clin Cancer Res. 2019 May 15;25(10):3063-3073.doi: 10.1158/1078-0432.CCR-18-2769. Epub 2019 Jan 28. PMID: 30692100.
  15. Reilly SW, Puentes LN, Schmitz A, Hsieh CJ, Weng CC, Hou C, Li S, Kuo YM,Padakanti P, Lee H, Riad AA, Makvandi M, Mach RH. Synthesis and evaluation of anAZD2461 [<sup>18</sup>F]PET probe in non-human primates reveals the PARP-1inhibitor to be non-blood-brain barrier penetrant. Bioorg Chem. 2019Mar;83:242-249. doi: 10.1016/j.bioorg.2018.10.015. Epub 2018 Oct 17. PMID:30390553; PMCID: PMC6378121.
  16. Zeng C, Weng CC, Schneider ME Jr, Puentes L, Riad A, Xu K, Makvandi M, JinL, Hawkins WG, Mach RH. TMEM97 and PGRMC1 do not mediate sigma-2 ligand-inducedcell death. Cell Death Discov. 2019 Jan 28;5:58. doi: 10.1038/s41420-019-0141-2.PMID: 30701090; PMCID: PMC6349905.
  17. Riad A, Zeng C, Weng CC, Winters H, Xu K, Makvandi M, Metz T, Carlin S, MachRH. Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization ofLDL by LDL Receptor through the Formation of a Ternary Complex. Sci Rep. 2018Nov 15;8(1):16845. doi: 10.1038/s41598-018-35430-3. PMID: 30443021; PMCID:PMC6238005.
  18. Reilly SW, Puentes LN, Wilson K, Hsieh CJ, Weng CC, Makvandi M, Mach RH.Examination of Diazaspiro Cores as Piperazine Bioisosteres in the OlaparibFramework Shows Reduced DNA Damage and Cytotoxicity. J Med Chem. 2018 Jun28;61(12):5367-5379. doi: 10.1021/acs.jmedchem.8b00576. Epub 2018 Jun 14. PMID:29856625; PMCID: PMC6047530.
  19. Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H,Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA,Simpkins F, Mach RH, Lin LL. A PET imaging agent for evaluating PARP-1expression in ovarian cancer. J Clin Invest. 2018 May 1;128(5):2116-2126. doi:10.1172/JCI97992. Epub 2018 Apr 16. PMID: 29509546; PMCID: PMC5919879.
  20. Hou C, Hsieh CJ, Li S, Lee H, Graham TJ, Xu K, Weng CC, Doot RK, Chu W,Chakraborty SK, Dugan LL, Mintun MA, Mach RH. Development of a Positron EmissionTomography Radiotracer for Imaging Elevated Levels of Superoxide inNeuroinflammation. ACS Chem Neurosci. 2018 Mar 21;9(3):578-586. doi:10.1021/acschemneuro.7b00385. Epub 2017 Dec 3. PMID: 29099578; PMCID:PMC5865080.
  21. Reilly SW, Griffin S, Taylor M, Sahlholm K, Weng CC, Xu K, Jacome DA,Luedtke RR, Mach RH. Highly Selective Dopamine D<sub>3</sub> ReceptorAntagonists with Arylated Diazaspiro Alkane Cores. J Med Chem. 2017 Dec14;60(23):9905-9910. doi: 10.1021/acs.jmedchem.7b01248. Epub 2017 Nov 21. PMID:29125762; PMCID: PMC5767125.
  22. Sellmyer MA, Lee I, Hou C, Weng CC, Li S, Lieberman BP, Zeng C, Mankoff DA,Mach RH. Bacterial infection imaging with [<sup>18</sup>F]fluoropropyl-trimethoprim. Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8372-8377. doi:10.1073/pnas.1703109114. Epub 2017 Jul 17. PMID: 28716936; PMCID: PMC5547613.
  23. Weng CC, Huang SL, Chen ZA, Lin KJ, Hsiao IT, Yen TC, Kung MP, Wey SP, HsuCH. [<sup>18</sup>F]FP-(+)-DTBZ PET study in a lactacystin-treated rat model ofParkinson disease. Ann Nucl Med. 2017 Aug;31(7):506-513. doi:10.1007/s12149-017-1174-3. Epub 2017 Apr 27. PMID: 28451991.
  24. Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao IT, Yen TC, KungMP, Hsu CH, Wey SP. Quantitative analysis of the therapeutic effect of magnololon MPTP-induced mouse model of Parkinson's disease using in vivo18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. PLoS One. 2017 Mar3;12(3):e0173503. doi: 10.1371/journal.pone.0173503. PMID: 28257461; PMCID:PMC5336287.
  25. Kung MP, Weng CC, Lin KJ, Hsiao IT, Yen TC, Wey SP. Amyloid plaque imagingfrom IMPY/SPECT to AV-45/PET. Chang Gung Med J. 2012 May-Jun;35(3):211-8. doi:10.4103/2319-4170.106151. PMID: 22735052.
  26. Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, Jan TR, Skovronsky D,Kung MP, Wey SP. GMP-compliant automated synthesis of [(18)F]AV-45 (FlorbetapirF 18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot. 2010Dec;68(12):2293-7. doi: 10.1016/j.apradiso.2010.07.001. Epub 2010 Jul 7. PMID:20638295.
  27. Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP.Validation of an (18)F-labeled biphenylalkyne as a positron emission tomographyimaging agent for beta-amyloid plaques. Nucl Med Biol. 2009 May;36(4):411-7.doi: 10.1016/j.nucmedbio.2009.01.013. Epub 2009 Mar 26. PMID: 19423009.
免費建立您的網站！ 此網站是在 Webnode 上建立的。今天開始免費建立您的個人網站！ 立即開始